Edgewise’s Early Cardiomyopathy Data Builds Case For A Blockbuster
Executive Summary
The EDG-7500 results have seen the company’s share price rocket, thanks to a potential advantage over existing treatments for the rare heart condition hypertrophic cardiomyopathy.